학술논문
Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab
ORIGINAL ARTICLE
ORIGINAL ARTICLE
Document Type
Report
Author
Source
Journal of the College of Physicians and Surgeons Pakistan. October 2022, Vol. 32 Issue 10, p1288, 7 p.
Subject
Language
English
ISSN
1022-386X
Abstract
INTRODUCTION Renal cell carcinoma (RCC) is the most common kidney cancer and constitutes 3% of all malignancies. (1) In comparison, 30% of them present with de-novo metastasis at the time [...]
Objective: To evaluate the utility of inflammatory prognostic index (IPI), albumin, c-reactive protein (CRP), and lactate dehydrogenase (LDH) as predictive biomarkers of oncologic outcome in metastatic renal cell cancer (mRCC) patients treated with nivolumab. Study Design: Descriptive study. Place and Duration of Study: Manisa Celal Bayar University, Ayd?n Adnan Menderes University, Bitlis Tatvan State Hospital and Private Hatay Defne Hospital Medical Oncology Clinics, Turkey, from January 2017 to June 2020. Methodology: Seventy-five mRCC patients treated with nivolumab between January 2017 and June 2020 were enrolled. Several factors were retrospectively investigated, including IPI, CRP, LDH, and albumin level, for their association with progression-free survival (PFS) and overall survival (OS). The IPI was calculated as CRP * NLR/albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: When analysed according to the calculated IPI score, it is seen that the group with Conclusion: Those with high IPI scores and low albumin levels were associated with worse median OS. However, only the multivariate analysis analysed albumin level as an independent prognostic variable. Prospective and more extensive research is needed to consolidate the potential prognostic power of these markers. Key Words: Albumin, Immune checkpoint inhibitor, IPI score, Metastatic renal cell carcinoma, Nivolumab, overall survival, Progression-free survival.
Objective: To evaluate the utility of inflammatory prognostic index (IPI), albumin, c-reactive protein (CRP), and lactate dehydrogenase (LDH) as predictive biomarkers of oncologic outcome in metastatic renal cell cancer (mRCC) patients treated with nivolumab. Study Design: Descriptive study. Place and Duration of Study: Manisa Celal Bayar University, Ayd?n Adnan Menderes University, Bitlis Tatvan State Hospital and Private Hatay Defne Hospital Medical Oncology Clinics, Turkey, from January 2017 to June 2020. Methodology: Seventy-five mRCC patients treated with nivolumab between January 2017 and June 2020 were enrolled. Several factors were retrospectively investigated, including IPI, CRP, LDH, and albumin level, for their association with progression-free survival (PFS) and overall survival (OS). The IPI was calculated as CRP * NLR/albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: When analysed according to the calculated IPI score, it is seen that the group with Conclusion: Those with high IPI scores and low albumin levels were associated with worse median OS. However, only the multivariate analysis analysed albumin level as an independent prognostic variable. Prospective and more extensive research is needed to consolidate the potential prognostic power of these markers. Key Words: Albumin, Immune checkpoint inhibitor, IPI score, Metastatic renal cell carcinoma, Nivolumab, overall survival, Progression-free survival.